One Lambda (OLI ) has signed a supply agreement with CellTrend, which allows OLI to market and distribute the Immuno-Assay product, EIA.
EIA is used for Quantitative Determination of anti-Angiotensin II Receptor 1 (AT1) Antibodies.
The application screens antibodies that form against Angiotensin II Type I Receptors (AT1R).
AT1R involves in various neurohumoral systems and expresses on cells of several bodily organs, including the heart, liver, lungs, kidneys and others.
Recent researches have examined the impact of non-HLA antibodies to AT1R in clinical outcomes of antibody-mediated rejection (AMR) in transplant patients.
The binding of antibodies to AT1R and AMR gives added information which may be used to determine immunological risk for organ transplant recipients.
The AT1R Immuno-Analysis can address the potential need for monitoring of non-HLA antibodies to AT1R.
OLI plans to start the AT1R Immuno-assay in the third quarter of the year.
CellTrend officials said, "We are very proud to work with One Lambda! Together we can offer the AT1R Biomarker Assay worldwide and help to improve transplant graft survival.
OLI Director of Marketing Stewart Han said, "One Lambda is delighted to have CellTrend part of their team and that the addition of the AT1R assay to the already comprehensive HLA antibody monitoring products, positions OLI at the forefront of transplant diagnostics."
